NanoStat™ Mucosal Vaccines

NanoBio also has an extensive mucosal vaccine development program.  The company’s nanoemulsion-based, intranasal vaccines have elicited robust immune responses in animals vaccinated against influenza, anthrax, hepatitis B, HIV, RSV and other diseases.  In some cases, the immune response is exponentially higher than what is required to provide adequate protection against infection.  NanoBio is in various stages of testing its pipeline of mucosal vaccines, and is currently implementing human and animal studies for selected vaccines.

NanoBio has shown that when either whole virus or a recombinant protein antigen is simply mixed with nanoemulsion and placed on the nanso pharynx, the nanoemulsion serves as a potent adjuvant, producing both mucosal immunity and systemic immune response.  This is accomplished without the need for additional immunostimulants through a process that involve the uptake of the nanoemulsion/antigen mixture by the dendritic cell.  This is due to the small size and high potential energy of the nanoemulsion droplet, and the efficiency by which the nanoemulsion is endocytosed by dendritic cells. 

Advantages of the nanoemulsion vaccines include:

• nasal delivery presents the antigen where it can most directly access the immune system
• development of rapid mucosal immunity followed by systemic immunity
• antigen-sparing capability
• thermally stable, requires no refrigeration
• needle-free, easy to administer